Redeye comments on today’s news of CEO replacement.
Redeyes view on the Q2 report. With a powerful report and above our estimates, we adjust our forecas...
Q2’22 NAVPS (SEK) -35% q-o-q and +4% y-o-y VEF trades at a 49% discount to NAVPS Solid cash position...
Safeture reported a Q2'22 which was more or less in line with Redeye's estimates and its own financi...
Net operating income -1% vs. ABGSCe Net leasing SEK 17m (-4m) and 62m TTM (18m) Now 20% below peers...
Teknikbolaget Appspotrs nettoomsättning uppgick till 1,7 miljoner kronor i årets andra kvartal, en ö...
Redeye comments on GiG ahead of its Q2-results (due 16 August) which will be the first quarter where...
Atria reported Q2 adjusted EBIT of EUR 13.8m, up from EUR 12.
Q2 sales in-line, adj. EBITA below (-16% vs ABGSCe) Adj.
Q2 report overshadowed by Kölvallen divestment Kölvallen to add SEK 690m to Q3 Value range at SEK 80...
Redeye considers Arise Q2 figures to be somewhat on the weak side, mainly due to weaker winds in the...
Q2 sales growth of 12.4% (2.8% organic) Sales estimates up ~1%, albeit with a lower EBIT margin New ...
Sales stabilising and EBITDA 7% above ABGSCe… … but macroeconomic environment could hurt demand ‘2...
God tillväxt men svagare marginal Justerad nettoomsättning i Q2 uppgick till 190 mkr (130 mkr Q2'21)...
Hansa Biopharma (Hansa) delivers another quarter with improved Idefirix European sales.
Old projects marked off – positive Likely a net seller in the coming quarters We trim rental income...
Sales 0% vs ABGSCe, organic growth of -4% Adj. EBITA -16% vs ABGSCe, -26% vs FactSet cons.
Q2 fairly in line with our expectations Estimates intact on isolated numbers 8.
Redeye retains its positive view of Efecte following a strong Q2 report, showing high SaaS growth an...
Redeye retains its positive view on Lagercrantz following a solid Q1 report with 9% organic growth a...
